MDNA 209

Drug Profile

MDNA 209

Alternative Names: MDNA209

Latest Information Update: 20 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer Medicenna Therapeutics
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Interleukin 15 inhibitors; Interleukin 2 receptor antagonists; Interleukin receptor common gamma subunit inhibitors; Interleukin-2 receptor beta subunit modulators; Natural killer cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 08 Mar 2017 Preclinical trials in Autoimmune disorders in Canada (unspecified route) (Medicenna communication, March 2017)
  • 08 Mar 2017 Preclinical trials in Inflammation in Canada (unspecified route) (Medicenna communication, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top